Share
The JCEM Case Reports Clinical Pearls session at ENDO 2025 featured three presentations of rare challenging endocrine cases that could answer questions for endocrinologists who could be treating patients with similar symptoms, possibly triggering further investigations that might lead to optimal outcomes. The audience for the third-annual JCEM Case Reports Clinical Pearls session at ENDO...
Share
From the pages of the Journal of the Endocrine Society, Endocrine News talks with Alan Rogol, MD, PhD, about the rarest of rare cases that involved growth hormone, Creutzfeldt-Jakob disease, and Alzheimer disease in a tale through time that involves rats, cadavers, and how one treatment evolved through scientific refinement. Has there ever been a...
Share
People with excess body fat who build and keep muscle may be less likely to develop obesity-induced heart, liver, or kidney damage or die early, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Despite clear evidence that excess body fat can directly cause illness, obesity is often viewed as a risk...
Share
Like many of you, I am still basking in the afterglow of yet another successful ENDO, as ENDO 2025 falls further and further away in the proverbial rearview mirror. Yes, I’m already anticipating ENDO 2026 in Chicago next June, but until that time, we have an issue packed with highlights from our standout event from...
Share
For decades, scientists have known that thyroid hormones play a pivotal role in regulating heart rate and other cardiovascular functions. An overactive thyroid, for example, can cause the heart to race, while an underactive one can slow it down. However, new research is revealing that this relationship is far more complex than previously understood, challenging...
Share
A new study from a poison control center in Alabama offers a reassuring perspective on the rising number of calls related to popular GLP-1 receptor agonists, such as Ozempic and Wegovy. While exposures to these medications have increased significantly over the past two decades, the research suggests many cases are accidental, associated with mild symptoms,...
Share
A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society. The therapies, known as Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), present an encouraging approach to treating alcohol and other substance use disorders. “Early...
Share
A new study in The Journal of Clinical Endocrinology & Metabolism has revealed a concerning paradox in the management of osteoporosis in the United States. While the use of drug therapies for the bone-weakening disease has increased over the last decade, a significant and persistent trend of underdiagnosis means millions of high-risk patients are missing...
